Dr. Amrendra Kumar, MD
Family Medicine (Family Medicine Physician)
1130 Hwy 9 Bypass W
Lancaster, SC 29720
Who else practices at this address →
Lancaster County is a federal mental health shortage area; it also includes primary care (55% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 220
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
SC license 29114
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Health Lancaster Medical Center Lancaster, SC
Medical groups
- Md-First Health Care LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 220
- Services billed
- 1,340
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg | 268 | 37 |
| Established patient office or other outpatient visit, 20-29 minutes | 217 | 132 |
| Established patient office or other outpatient visit, 30-39 minutes | 201 | 109 |
| Injection of drug or substance under skin or into muscle | 106 | 82 |
| Injection, ceftriaxone sodium, per 250 mg | 98 | 22 |
| Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | 84 | 74 |
| Detection test by immunoassay with direct visual observation for influenza virus | 68 | 34 |
| Injection, ketorolac tromethamine, per 15 mg | 66 | 28 |
| Urinalysis, manual test | 64 | 45 |
| Established patient office or other outpatient visit, 40-54 minutes | 60 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 9 payments worth $280 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $150 |
|---|---|
| Exact Sciences Corporation | $56.15 |
| Stryker Corporation | $20.35 |
| Alk-abello, Inc | $20.18 |
| Pfizer Inc. | $18.57 |
| Cipher Pharmaceuticals US LLC | $14.68 |
| Food and Beverage | $280 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $342,726 in research payments for these studies, mostly to the institutions running them.
- A Multi-Site Clinical Evaluation of the LIAISON NES Group A Strep (GAS) Assay in Symptomatic Patients (DSM-PROT-005254)
Diasorin Molecular LLC - A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company · Completed · NCT05971940 - A multi-center, randomized, double-blind, parallel-group, placebo-cont
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.